GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis, Inc., a pre-clinical biotech company transforming the treatment ...

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet ...

CellFE®, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced ...

I welcome the opportunity of sharing novel information about our company and the secreted form of the Klotho anti-aging gene, ’s-KL’, the patent protected development platform on which our product ...

Financial technology and capital markets firm Clear Street launched its healthcare and biotechnology equity research last month ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced today announced its ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...

Cognition Therapeutics, Inc., (the "Company” or "Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43 rd Annual J.P ...

This bond group, which features an integrated mix of legacy Morgan Stanley and Eaton Vance teams, has bright spots in credit strategies but is only average in other fixed-income sectors.